1. Anonymous, MRC/BHF Heart Protection Study of cholesterol lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease, death, early safety, and efficacy experience. European Heart Journal, 1999. 20: p.725-41.
2. Anonymous, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 1998. 339: p.1349-57.
3. Arnett, D.K., et al. Twenty year trends in serum cholesterol, hypercholesterolemia and cholesterol medication use, 1980-2002, Circulation (December 20, 2005), Vol. 112.
4. Bradford, R.H., et al. Expanded clinical evaluation of lovastatin (EXCEL) study design and patient characteristics of a double blind, placebo controlled study in patients with moderate hypercholesterolemia. American Journal of Cardiology, 1990. 66: p.44B-55B.
5. Bradford, R.H., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia [see comments]. Archives of Internal Medicine, 1991. 151: p.43-9.
6. Bradford, R.H., et al. Expanded clinical evaluation of lovastatin (EXCEL) study results III . Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. American Journal of Medicine, 1991. 91:p.18S-24S.
7. Bradford, R.H., et al. Efficacy and tolerability of lovastatin in 3,390 women with moderate hypercholesterolemia. Annals of Internal Medicine, 1993. 118: p.850-5.
8. Bradford, R.H., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, two year efficacy and safety follow up. American Journal of Cardiology, 1994. 74: p.667-73.
9. Cannon, C.P., et al. Intensive and moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 2004. 350(15): p.1495-1504.
10. Cannon, C.P., The IDEAL cholesterol: lower is better, JAMA (Nov. 16, 2005), 294:2492-2494. Carrol, M.D., et al. Trends in serum lipids and lipoproteins of adults, 1960-2002, JAMA (Oct. 12, 2005), Vol 294: 1773-1781.
11. Davidson, M.H., et al. Lipid-altering efficacy and safety of simvastatin 80mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutrition Metabolism & Cardiovascular Diseases, 2000. 10(5): p.253-62.
12. de Lemos, J.A., et al. Early Intensive vs. a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial. JAMA, 2004.
13. Downs, J.R., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998. 279: p.1615-22.
14. “Drugs for Lipids,” The Medical Letter (February 2008), Issue 66.
15. Fox. R., et al. Ezetimibe and statin-associated myopathy, Ann. Int. Med (April 2004), Vol. 140: 671-672.
16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al; National Heart, Lung, and Blood Institute. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
17. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002. 360: p. 7-22.
18. Kent, D.M. Stroke–an equal opportunity for the initiation of statin therapy. New England Journal of Medicine (Aug. 10, 2006); 355: 613-615.
19. LaRosa, J.C., J. He, and S. Vupputuri. Effect of statins on risk of coronary disease: a metaanalysis of randomized controlled trials. JAMA, 1999. 282(24): p.2340-6.
20. Paaladinesh, T., et al. Primary prevention of cardiovascular diseases with statin therapy; a metaanalysis of randomized controlled clinical trials, Archives of Internal Medicine (Nov. 27, 2006); 166:2307-2313.
21. Pedersen, T.R., et al. High-dose atorvastatin vs. usual dose simvastatin for secondary prevention after myocardial infarction–The IDEAL study. JAMA (Nov. 15, 2005), 294:2437-2445.
22. Pedersen, T.R., Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease The Scandinavian Simvastatin Survival Study (4S). Lancet, 1994. 344: p.1383-1389.
23. Sacks, F.M., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine, 1996. 335(14): p. 001-9.
24. Serruys, P., et al. The Lescol (R) Intervention Prevention Study (LI PS): A double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. International Journal of Cardiovascular Interventions., 2001. 4(4): p.165-172.
25. Serruys, P.W., et al. Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention: A Randomized Controlled Trial. JAMA, 2002. 287:p.3215-3222.
26. Sever, P.S., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. [comment]. Lancet, 2003. 361(9364): p. 1149-58.
27. Sever, P.S., et al. Rationale, design, methods, and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. Journal of Hypertension, 2001. 19(6): p.1139-47.
28. Sever, P.S., et al. Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale, and outline protocol. Journal of Human Hypertension, 2001.15 (Suppl 1): p.S11-2.
29. Sharma M, Ansari MT, Abou-setta AM, Soares-Weiser K, Ooi TC, Sears M, et al., Systematic Review: Comparative Effectiveness and Harms of Combinations of Lipid-Modifying Agents and High-Dose Statin Monotherapy. Ann. Int. Med. 2009;151.
30. Shepherd, J., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine, 1995. 333(20): p.1301-7.
31. Taylor, F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD004816. DOI: 10.1002/14651858.CD004816.pub5.
32. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, high-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine (Aug. 10, 2006); 355: 549-59.